PDF(Pubmed)
Abstract：
We investigated the prognostic significance and treatment outcomes of pretreatment inflammatory response markers for locally advanced squamous cell carcinoma (SCC) of the external auditory canal (EAC) and middle ear (ME). Between July 2003 and July 2019, 21 patients with SCC of the EAC (n = 18) or ME (n = 3) who received radiotherapy with or without surgery or systemic therapy (radiotherapy alone [n = 2], radiotherapy + systemic therapy [n = 6], radiotherapy + surgery [n = 7], radiotherapy + surgery + systemic therapy [n = 6]) were retrospectively examined. The median radiation dose was 66.0 (range, 50.4-70.0) Gy, with daily fractions of 1.8-2.0 Gy. The median follow-up period was 25 months (range, 6-137). The two-year overall survival (OS), progression-free survival (PFS), and locoregional control (LC) rates were 61%, 48%, and 55%, respectively. OS, PFS, and LC did not differ significantly according to patient- (age, sex), tumor- (Pittsburgh stage, pretreatment neurological findings), and treatment-related (surgery or systemic therapy, radiation dose, prophylactic neck irradiation) factors. Conversely, there were significant differences in OS, PFS, and LC between patients with high and low pretreatment C-reactive protein-to-albumin ratios (p = 0.002, 0.003, and 0.004, respectively). OS also differed significantly between patients with high and low pretreatment neutrophil-to-lymphocyte ratios (NLR; p = 0.037). Other inflammatory response markers, including platelet-to-lymphocyte ratio (PLR) and albumin-to-globulin ratio (AGR), did not influence OS, PFS, or LC. Our findings suggest that pretreatment C-reactive protein-to-albumin ratio and NLRs have a significant impact on treatment outcomes in patients with locally advanced SCC of the EAC and ME.
摘要：
我们调查了外耳道（EAC）和中耳（ME）局部晚期鳞状细胞癌（SCC）的预处理炎症反应标志物的预后意义和治疗结果。在2003年7月至2019年7月之间，有21例EAC的SCC（n=18）或ME（n=3）患者接受了有或没有手术或全身治疗的放疗（单纯放疗[n=2]，放疗+全身治疗[n=6]，放疗+手术[n=7]，放疗+手术+全身治疗[n=6])进行回顾性检查。中位辐射剂量为66.0（范围，50.4-70.0)Gy,每日分数为1.8-2.0Gy。中位随访期为25个月(范围,6-137）。2年总生存期(OS),无进展生存期（PFS），局部控制率(LC)为61%，48%,55%,分别。操作系统,PFS,根据患者的不同，LC没有显著差异-(年龄，sex),肿瘤-(匹兹堡舞台，预处理神经学发现)，和治疗相关(手术或全身治疗，辐射剂量,预防性颈部照射）因素。相反，操作系统存在显著差异，PFS,治疗前C反应蛋白与白蛋白比值高和低的患者之间的LC（分别为p=0.002、0.003和0.004）。治疗前中性粒细胞与淋巴细胞比率高和低的患者之间的OS也存在显着差异（NLR；p=0.037）。其他炎症反应标志物，包括血小板与淋巴细胞比率（PLR）和白蛋白与球蛋白比率（AGR），没有影响操作系统，PFS,或LC。我们的研究结果表明，治疗前C反应蛋白与白蛋白的比值和NLRs对EAC和ME局部晚期SCC患者的治疗结果有显著影响。
